flanders.bio provides you with insights in the vibrant life sciences sector

 

News from flanders.bio and its members

Bloeiende Belgische biotech en digital sciences bundelen de krachten

De Belgische biotech doet het goed. Om verder te groeien, onder andere op vlak van gepersonaliseerde geneeskunde, wordt er nu volop ingezet op een nauwe samenwerking met de eveneens bloeiende digital sciences. Willem Dhooge, co-General Manager van flanders.bio, legt uit.

Entrepreneurship | 10 December 19
Read more
10
Dec
2019

Bloeiende Belgische biotech en digital sciences bundelen de krachten

De Belgische biotech doet het goed. Om verder te groeien, onder andere op vlak van gepersonaliseerde geneeskunde, wordt er nu volop ingezet op een nauwe samenwerking met de eveneens bloeiende digital sciences. Willem Dhooge, co-General Manager van flanders.bio, legt uit.

10
Dec
2019

AgroSavfe announces name change to Biotalys and incorporation of US subsidiary, Biotalys, Inc.

AgroSavfe NV, a rapidly growing and transformative Food and Crop protection company developing a new generation of protein-based biocontrols, today announces that its company name changes to “Biotalys”. As a result, AgroSavfe NV becomes Biotalys NV, effective immediately. In addition, to further support its international growth and to prepare the launch of its first biofungicide, expected in 2022 in the USA, the Company has incorporated Biotalys, Inc. The Company’s headquarters remain based in the biotech hub in Ghent, Belgium.

7
Dec
2019

argenx Announces Receipt of First Milestone Payment under Janssen Collaboration and Provides Data Update from Phase 1 Dose Escalation Trial of Cusatuzumab in Acute Myeloid Leukemia at ASH Annual Meeting

-argenx to receive $25 million from Janssen for achievement of enrollment milestone in first Phase 2 trial under collaboration

5
Dec
2019

Mithra Signs LSA for Commercialization of Myring™ in Switzerland

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into a license and supply agreement with Labatec for the commercialization of its hormonal contraceptive ring Myring™ in Switzerland.

5
Dec
2019

Galapagos completes recruitment of NOVESA trial in systemic sclerosis

(Euronext & NASDAQ: GLPG) has completed recruitment for the NOVESA Phase 2 clinical trial with GLPG1690.

10
Dec
2019

Bloeiende Belgische biotech en digital sciences bundelen de krachten

De Belgische biotech doet het goed. Om verder te groeien, onder andere op vlak van gepersonaliseerde geneeskunde, wordt er nu volop ingezet op een nauwe samenwerking met de eveneens bloeiende digital sciences. Willem Dhooge, co-General Manager van flanders.bio, legt uit.

10
Dec
2019

AgroSavfe announces name change to Biotalys and incorporation of US subsidiary, Biotalys, Inc.

AgroSavfe NV, a rapidly growing and transformative Food and Crop protection company developing a new generation of protein-based biocontrols, today announces that its company name changes to “Biotalys”. As a result, AgroSavfe NV becomes Biotalys NV, effective immediately. In addition, to further support its international growth and to prepare the launch of its first biofungicide, expected in 2022 in the USA, the Company has incorporated Biotalys, Inc. The Company’s headquarters remain based in the biotech hub in Ghent, Belgium.

7
Dec
2019

argenx Announces Receipt of First Milestone Payment under Janssen Collaboration and Provides Data Update from Phase 1 Dose Escalation Trial of Cusatuzumab in Acute Myeloid Leukemia at ASH Annual Meeting

-argenx to receive $25 million from Janssen for achievement of enrollment milestone in first Phase 2 trial under collaboration

5
Dec
2019

Mithra Signs LSA for Commercialization of Myring™ in Switzerland

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into a license and supply agreement with Labatec for the commercialization of its hormonal contraceptive ring Myring™ in Switzerland.

5
Dec
2019

Galapagos completes recruitment of NOVESA trial in systemic sclerosis

(Euronext & NASDAQ: GLPG) has completed recruitment for the NOVESA Phase 2 clinical trial with GLPG1690.

Facts & Figures

CONSULT OUR LIFE SCIENCE DATABASE

 

Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.

 

Not only extensive life sciences facilities support this high-level technology industry but also financial benefits for R&D companies, international collaborations that guarantee regular cash flow, world known educational systems, a promising product pipeline, and Belgium’s unique central location in Europe.

 

Belgium concentrates on a small territory (30,528 km2) more than 300 life sciences companies with biotech activities. In total, the life sciences sector employs more than 30,000 people (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to healthcare, but Belgium also has a strong representation of agricultural and industrial biotech companies.

 

The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.

 

Additional assets of Belgium includes: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.

Z Life Sciences

A look behind the scenes of the vibrant life sciences sector in Flanders, Belgium in 11 episodes.

1

VIB

VIB is a life sciences research institute based in Flanders. With more than 1470 scientists from over 60 countries, they perform basic research into the molecular foundations of life and they translate this research into pharmaceutical, agricultural and industrial applications.

2

imec

imec performs world-leading research in nano-electronics and creates groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, and energy. The combination of their widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes imec unique.

3

Bio Base Europe Pilot Plant

Bio Base Europe Pilot Plant is an independent, state-of-the-art facility that operates from a laboratory level to a multi-ton scale. Bio Base Europe Pilot Plant provides process development, scale-up and custom manufacturing of biobased products and processes. 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?